Robert Lisicki - Aug 3, 2021 Form 4 Insider Report for ARENA PHARMACEUTICALS INC (ARNA)

Role
EVP, Chief Commercial Officer
Signature
/s/ Andrew J. Cronauer, as Attorney-in-Fact
Stock symbol
ARNA
Transactions as of
Aug 3, 2021
Transactions value $
-$334,857
Form type
4
Date filed
8/5/2021, 06:08 PM
Next filing
Jan 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARNA Common Stock Options Exercise $717K +17.5K +108.69% $40.95 33.6K Aug 3, 2021 Direct F1
transaction ARNA Common Stock Sale -$335K -5.61K -16.68% $59.84 28K Aug 3, 2021 Direct F1, F2
transaction ARNA Common Stock Sale -$716K -11.9K -42.49% $60.20 16.1K Aug 3, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARNA Employee Stock Option (right to buy) Options Exercise $0 -17.5K -13.73% $0.00 110K Aug 3, 2021 Common Stock 17.5K $40.95 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this line item of this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.63 to $59.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.74, inclusive.
F4 The options vest over four years, with 25% of the shares subject to the option vesting on November 26, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.